3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Polycystic Ovary Syndrome
21
Glioblastoma
5
Endometrial Neoplasms
5
Breast Neoplasms
5
Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Prostatic Neoplasms
3
Leukoplakia, Oral
3
Insulin Resistance
3
Ovarian Neoplasms
2
Metabolic Syndrome
2
Metabolic Diseases
2
Medulloblastoma
2
Infertility
2
Erythroplasia
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Intraductal, Noninfiltrating
2
Adenocarcinoma Of Esophagus
2
Weight Loss
1
Uterine Cervical Neoplasms
1
Urothelial Cancer
1
Thyroid Diseases
1
TP53 Y220C Mutation
1
Smoldering Multiple Myeloma
1
Sarcoma
1
Rectal Neoplasms
1
Prostate Cancer Recurrent
1
Prediabetic State
1
Posterior Fossa Ependymal Tumor
1
Pleural Effusion, Malignant
1
Interventions
pembrolizumab
59
Cisplatin
45
Cetuximab
29
Radiotherapy
26
Carboplatin
24
Docetaxel
17
Paclitaxel
16
Nivolumab
16
Surveys and Questionnaires
15
Radiotherapy, Intensity-Modulated
13
Fluorouracil
12
Drug Therapy
12
Blood Specimen Collection
11
Standard of Care
8
tislelizumab
7
cemiplimab
6
atezolizumab
6
Radiation
6
Chemoradiotherapy
6
toripalimab
5
Cyclophosphamide
5
130-nm albumin-bound paclitaxel
5
nimotuzumab
4
fludarabine
4
durvalumab
4
dostarlimab
4
Surgical Procedures, Operative
4
Afatinib
4
palbociclib
3
niraparib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
Metformin
×
1 year
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled